---
title: "VK2735 in Chronic weight management: Special populations"
description: "Formulary evidence on VK2735 in Chronic weight management: Special populations. Topics: Subcutaneous formulation: adults with type 2 diabetes in VANQUISH-2, Oral formulation: adults with type 2 diabetes in SUNRISE-2, Subcutaneous formulation: adults with diabetes excluded from VANQUISH-1 and the phase 2 trial, Oral formulation: adults with diabetes excluded from SUNRISE-1, and 8 further topics. 12 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/special-populations"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Subcutaneous formulation: adults with type 2 diabetes in VANQUISH-2

> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening”
> “Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-2.1.2.8-2"></a>

### Oral formulation: adults with type 2 diabetes in SUNRISE-2

> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-2.1.2.8-3"></a>

### Subcutaneous formulation: adults with diabetes excluded from VANQUISH-1 and the phase 2 trial

> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

> “Participants with BMI > 50 kg/m”
> “or with certain medical conditions, including diabetes, were not eligible.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.8-4"></a>

### Oral formulation: adults with diabetes excluded from SUNRISE-1

> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). If a participant has had gestational diabetes, they are allowed to be enrolled as long as the glycemic status has returned to normal levels after 12 months of completion of pregnancy”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-2.1.2.8-5"></a>

### Pediatric participants: minimum age in the phase 3 trials

> “Age ≥18 years of age at the time of signing the informed consent”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-2.1.2.8-6"></a>

### Pediatric participants: clinical data with either formulation

No evidence found.

<a id="topic-2.1.2.8-7"></a>

### Subcutaneous formulation: age range in the phase 1 study

> “Healthy volunteers, and otherwise healthy volunteers who have an increased body mass index, between the ages of 18 and 65 years.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-2.1.2.8-8"></a>

### Oral formulation: age of participants in the phase 2 trial

> “Mean age was 51 years for entire population, 83% of participants were <65 years”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-2.1.2.8-9"></a>

### Renal impairment: exclusion criteria

> “Impaired renal function”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “Impaired renal function with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 as measured at Screening.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-2.1.2.8-10"></a>

### Hepatic impairment: exclusion criterion in the maintenance study

> “Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level > 3.0 times the ULN for the reference range.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-2.1.2.8-11"></a>

### Renal or hepatic impairment: pharmacokinetic data with either formulation

No evidence found.

<a id="topic-2.1.2.8-12"></a>

### Pregnancy and contraception: requirements in the phase 1 studies

> “Willing to comply with contraceptive requirements.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

> “Willing to comply with contraception requirements”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-2.1.2.8-13"></a>

### Pregnancy and lactation: clinical data with either formulation

No evidence found.

<a id="topic-2.1.2.8-14"></a>

### Class context: pregnancy in the tirzepatide (Zepbound) prescribing information

> “Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue ZEPBOUND.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.1.2.8-15"></a>

### Subcutaneous formulation: demographic enrollment goals in VANQUISH-1

> “Enrollment goals specified to achieve inclusive trial participation reflective of the real-world demographic”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
